Proof of Concept, Feasibility, and Safety of Local Anticholinesterase Treatment for Neuromodulator-Induced Facial Muscle Paralysis.

Summary

This first-in-human, placebo-controlled Phase 1 study shows that local injection of an anticholinesterase can rapidly reverse cosmetic onabotulinumtoxinA-induced facial muscle weakness, with effects evident within 15 minutes and no major or persistent adverse events. No placebo-treated participant responded, supporting pharmacologic specificity.

Key Findings

• Local anticholinesterase injection reversed cosmetic onabotulinumtoxinA-induced facial muscle weakness in most treated subjects.
• No placebo-treated subject exhibited reversal, indicating a specific pharmacologic effect.
• Onset of reversal occurred within 15 minutes, with no major or persistent adverse events reported.

Clinical Implications

If validated in larger trials, clinicians could promptly reverse unintended facial paresis after cosmetic botulinum toxin injections, improving patient safety, satisfaction, and medicolegal risk.

Limitations

• Small Phase 1 sample with short observation window limits generalizability
• Optimal dosing, distribution, and formulation remain undetermined

Future Directions

Conduct dose-finding and Phase 2/3 trials to define efficacy, safety, dosing algorithms, injection patterns, and candidate anticholinesterase agents across facial muscle groups.